In re Abbott Laboratories Derivative Shareholders Litigation

United States Court of Appeals for the Seventh Circuit · 2001 · Corporations

CorporationsShareholder derivative suitsDemand futilityDirector oversightderivative actionRule 23.1demand futilityAronson

Facts

For six years, Abbott's diagnostics division was repeatedly cited by the FDA for regulatory violations through inspections, Forms 483, warning letters, and a failed voluntary compliance plan. The complaint alleged the board knew of these ongoing violations through warning letters copied to the chairman, audit committee responsibilities, SEC filings signed by directors, meetings with senior officers, and public reports, yet took no corrective action. In 1999 Abbott entered a consent decree requiring a $100 million civil fine, withdrawal of 125 diagnostic kits from the United States market, destruction of certain inventory, and corrective manufacturing changes, causing major losses. The shareholders did not make a pre-suit demand, alleging that demand was futile because the directors who would consider it were the same directors who allegedly ignored the violations.

Issue

Whether the shareholders pleaded demand futility with sufficient particularity to excuse a pre-suit demand on Abbott's board. Also, whether Abbott's director exculpation provision barred the suit at the pleading stage.

Rule

Under Illinois law following Delaware law, demand is excused when particularized facts create a reasonable doubt that the challenged board action or conscious inaction is protected by the business judgment rule under Aronson. Where the complaint supports a reasonable inference that directors knew of ongoing legal violations and, over a sustained period, failed to act in good faith, demand may be excused; exculpation provisions do not warrant dismissal at the pleading stage when the complaint sufficiently alleges omissions not in good faith, intentional misconduct, or knowing violations of law.

🔒

See the holding & full analysis

Create a free KwikCourt account to unlock the rest of this brief — and practice the case.

The court's holding and reasoning
Doctrine tests, pitfalls & exam hypotheticals
10 practice questions + 4 AI-graded essays on this case

Free sample · practice this case

Test yourself

One of 10 multiple-choice questions for this case. Pick an answer to see why.

Crescent Biomed, an Illinois corporation based in Chicago, manufactures hospital sterilization equipment. For four years, the same nine directors who still sit on the board received repeated state safety citations, compliance reports to the audit committee, and public articles describing recurring violations, yet the board took no corrective action before the company paid a major regulatory penalty.

Shareholders file a derivative suit without making demand, alleging the directors knowingly allowed the violations to continue. Which demand-futility framework should a court apply?

Explanation. The majority held that Aronson, not Rales, governs where particularized facts support a reasonable inference that the board knew of ongoing violations and effectively decided that no action was required. Rales is not triggered merely because plaintiffs characterize the case as inaction. When the same board allegedly knew and consciously failed to respond, the complaint challenges board action or conscious inaction for Aronson purposes. (Derived from In re Abbott Laboratories Derivative Shareholders Litigation (2001).)